Loading company
Viking Therapeutics, Inc.
VKTX · Nasdaq · ·
Next earnings: October 28, 2026
$31.81-3.8%Sep 29 close
- 1M
- -1.1%
- 6M
- +6.3%
- 1Y
- +21.0%
- 5Y
- +376.9%
VKTX · Nasdaq · ·
Next earnings: October 28, 2026
$31.81-3.8%Sep 29 close
Viking Therapeutics, Inc. is scheduled to report next on October 28, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$128M | -$65.6M | -95.27% |
| Profit per share | -$1.10 | -$0.58 | -89.66% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Viking Therapeutics, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Viking Therapeutics, Inc. is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Viking Therapeutics, Inc.’s Item 2.02 8-K filed July 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.